Nanoform Finland Oyj : Avanza Börsdag

Nanoforming the future of medicine

Management Presentation

November 18th, 2020

Nanoform is an innovative nanoparticle medicine enabling company with headquarters in Helsinki, Finland. The Company's patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform's share is listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Nanoform is researched by SEB, Danske Bank, Kepler Cheuvreux and Stifel. www.nanoform.com

Introduction to Nanoform

CEO Edward Hæggström

The structural pharma R&D problem

Only 48 drugs approved in the US last year…	…while the global pharma industry R&D expenditure exceeds USD 180bn
Annual number of novel drug approvals by FDA 2010-2019	Global pharmaceutical R&D spending 2010-2024E (USDbn)

				Chemical		Biologics
60										250
50									17	200									189	196	202	207	213
																179	182
40						12		12		10						160	168
												145	150
									150
			6		11						137	136	138
								129
30
		6		2						100
20							7		42	38
6
		33			33	34
				30
				25					50
10		24
15						15
0										0
	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019

• A game changer in particle design is needed to improve R&D yield

Source: U.S. Food and Drug Administration (FDA), New Drug Therapy Approvals 2019 (Annual number of drugs approved); EvaluatePharma, World	3
Preview 2019, Outlook to 2024 (Annual R&D spend)

Low bioavailability is the key issue

Poor bioavailability and low efficacy most common reasons for drug failure

Reasons for drug failure in pre-clinical trials (share of molecules)

45%
40%
35%
30%
25%
20%		39%
15%					30%
10%
						11%
5%							10%	10%
0%
	Poor	Low efficacy	High toxicity	Adverse effects	Others
	bioavailability

Majority of new drugs suffer from poor solubility
	Solubility
	High	Low
	Class I1	Class II1
High	On market: 35%	On market: 30%
New drugs: 5-10%	New drugs: 60-70%
Permeability		70-90%
	of new drugs
		are poorly
		soluble
Low	Class III1	Class IV1
On market: 25%	On market: 10%
	New drugs: 5-10%	New drugs: 10-20%

• Nanoform can enhance the pharma industry output by targeting poorly soluble drugs

Source: GlobalData 2009, Cutting Edge Water-based Nanotechnology in Drug Development (Reasons for drug failure); Nikolakakis & Partheniadis	4
(2017), Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release (Share of poorly soluble
drugs)

1) Classification of drug substance according to Biopharmaceutics Classification System (BCS)